Table 4 Medications given to participants within the last 24 h before testing in sample II
|
Buprenorphine or Buprenorphine/ Naloxone (n= 18) |
Methadone (n= 18) | Group or time point comparison p-values | |
|---|---|---|---|
|
Opioid drug, dose (M ± SD (range) ) | |||
| T2 |
22 ± 5 mg ( 10 - 28 mg) | - | T2 vs. T3, ns |
| T3 |
21 ± 6 mg ( 6 - 30 mg) | - | |
| T2 | - |
119. ± 33 mg (80 - 180 mg) | T2 vs. T3, ns |
| T3 | - |
129 ± 33 mg (75 - 180 mg) | |
| Participants using BZD medication | |||
| T2/T3 | 78%/67% | 89%/94% | ns/ns |
| BZD dose at T2 (M ± SD (range)) |
20 ± 16 mg (0 - 60 mg) |
21 ± 16 mg (0 - 70 mg) |
T2 vs. T3, ns
ns |
| BZD dose at T3 (M ± SD (range)) |
16 ± 14 mg (0 - 40 mg) |
20 ± 10 mg (0 - 40 mg) |
ns
T2 vs. T3, ns |
| Number of other medications with possible cognitive effects a | |||
| T2/T3 (M ± SD ; (range)) | 1.8 ± 1.1 (0 - 3) | 2.2 ± 0.7 (1 -4) | ns |
| 1.9 ± 1.4 (0 - 4) | 2.0 ± 1.0 (1 - 4) | ns | |
| T2 vs. T3, ns |